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Abstract
Purpose Using the low mechanical index (MI) contrast
mode and the high MI contrast mode of contrast-enhanced
ultrasonography, we evaluated which method is more
sensitive for detecting Sonazoid microbubbles in the liver
of normal subjects.
Methods Thirteen normal subjects received an intra-
venous bolus injection of 0.2 mL of Sonazoid. We defined
the intensity difference as the intensity post-injection
minus the intensity pre-injection. We evaluated the inten-
sity difference at the portal vein using both the low MI
(0.21–0.23) and the high MI (0.7–1.2) at 1 min, at every
10 min between 10 to 60 min, and at every 30 min
between 60 to 300 min post-injection. The intensity dif-
ference at the liver parenchyma was also evaluated at eight
points (1, 10, 30, 60, 120, 180, 240, and 300 min) using the
low MI and at three points (1, 10, and 300 min) using the
high MI.
Results The intensity differences at the portal vein mea-
sured using high MI were significantly higher than those
measured using the low MI at each point between 1 and
240 min (P\ 0.01) and at 270 min post-injection
(P\ 0.05). The intensity differences at the liver
parenchyma measured using the high MI were also sig-
nificantly higher than those measured using the low MI at
each time point (P\ 0.01).
Conclusion Compared with the low MI, the high MI is
more sensitive for detecting Sonazoid microbubbles in the
liver of normal subjects.
Keywords Contrast-enhanced ultrasonography  Low
mechanical index contrast mode  High mechanical index
contrast mode  Intensity difference  Sonazoid
microbubbles
Introduction
Sonazoid (Daiichi Sankyo, Tokyo, Japan), a second-gen-
eration formulation of a lipid-stabilized suspension of a
perfluorobutane gas microbubble contrast agent, has been
used clinically in Japan for patients with liver tumors and
for harmonic gray-scale ultrasonography (US) since Jan-
uary 2007 [1–6]. Sonazoid microbubbles have a higher
stability [6, 7] than other second-generation ultrasound
contrast agents, such as SonoVue (Bracco, Milan, Italy)
[8]. The two contrast agents mentioned above can be used
to evaluate vascular phase images. In addition to the vas-
cular phase, Sonazoid can be used to scan the entire liver
repeatedly using a low mechanical index (MI) contrast
mode, providing detailed post-vascular phase images [9].
In contrast, SonoVue, which requires a low MI contrast
mode, has a delayed phase (120 s post-injection), but it
does not have a post-vascular phase [8]. This difference can
likely be explained by the fact that only 7.3 % of injected
SonoVue was phagocytosed by reticuloendothelial (Kupf-
fer) cells in rats, whereas 99 % of Sonazoid were phago-
cytosed [10].
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There are two ways to demonstrate a contrast effect on
contrast-enhanced (CE) USwith Sonazoid: a lowMI contrast
mode at a lowMI, and a highMIcontrastmode at a highMI [6,
11–16]. The former method enables repeated observations of
the liver in a real-time manner because the microbubbles
undergo less breakdown. However, the evaluation of contrast
findings for deeply located hepatic lesions might not be fea-
sible because of the attenuation of the US beam. Another
potential limitation of this mode is the difficulty in assessing
perfusion defects in hyperechoic nodules since the pre-en-
hancement echogenicity may affect the post-enhancement
appearance. On the other hand, the latter makes microbubble
breakdown easier and could eliminate theB-mode signal from
background tissue. A previous study showed the usefulness of
a high MI technique for deeply located hepatic lesions and
hyperechoic nodules [6, 12–16]. Although there might be a
difference in the sensitivity for the detection of Sonazoid
microbubbles between the low MI and the high MI contrast
modes, little is known about the detectability under different
contrast modes at different MI settings.
Against this background, we performed CEUS with
Sonazoid using both the low MI and the high MI contrast
modes in the liver of normal subjects and compared the
intensity difference before and after the Sonazoid injection.
The aim was to investigate MI-related differences (low MI
contrast mode at a low MI versus high MI contrast mode at
a high MI) in microbubble detectability when performing
CEUS with Sonazoid.
Materials and methods
Subjects
This prospective study was approved by our institutional
review board, and written informed consent was obtained
from each subject. This study was conducted between
September 2012 and May 2014. A total of 13 normal
volunteers (11 males and 2 females) who were at least
20 years old were enrolled in this study. None of the
subjects had cardiovascular-respiratory diseases or liver
diseases (including fatty liver). All of the subjects’ asparate
aminotransferase, alanine aminotransferase, and c-
glutamyl transpeptidase values were within the normal
ranges. Apparently obese subjects were not included in this
study. Subject characteristics are summarized in Table 1.
Methods
CEUS procedure
To avoid the influence of increases in portal venous flow
caused by diet [17], all the examinations were performed
after the subjects had fasted. No foods or liquidswith calories
were ingested until the end of the examination. During the
study, all the subjects remained lying down quietly.
CEUS was performed using the LOGIQ7 ultrasound sys-
tem (GEHealthcare,Milwaukee,WI)with a 3.5-MHz convex
probe. The focus position was set at under the right branch of
the portal vein (Fig. 1c). We used the low MI contrast mode
(coded phase inversion mode) at a low MI (transmission
power, 20–35 %; MI, 0.21–0.23) and the high MI contrast
mode (coded harmonic angio mode) at a high MI (transmis-
sion power, 100 %; MI, 0.7–1.2) at 2 frames per second: we
called thismethod ‘‘highMI intermittent imaging’’ [6, 12–16].
Sonazoid was used as the contrast agent. All 13 subjects
Table 1 Characteristics of
normal subjects
Characteristics
No. of subjects 13
Age (mean ± SD, range; years) 42.8 ± 9.7, 25–62
Sex male/female 11/2
Body weight (mean ± SD, range; kg) 65.1 ± 7.8, 51–83
Body height (mean ± SD, range; m) 1.69 ± 0.05, 1.61–1.77
Body mass index (mean ± SD, range; kg/m2) 22.5 ± 2.0, 19.7–26.5
Fig. 1 Measurement of the intensity at the portal vein and in the liver
parenchyma. a For CEUS images obtained using the low MI and the
high MI contrast modes, the operator manually set a region of interest
(ROI) with a diameter of 0.59 cm within the portal vein. b Three
ROIs, each with a diameter of 1.2 cm, were set vertically, and the
intensity of the liver parenchyma was measured; the ROIs were
placed so as to avoid relatively large vascular structures, such as the
portal vein or the hepatic vein. c We set the focus position at a depth
that enabled a ROI to be placed on the right branch of the portal vein
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received an intravenous bolus injection of 0.2 mL of Sona-
zoid, followed by 2 mL of 5 % glucose solution [6, 12–16].
Quantitative analysis of US images
Recording of US images
Using conventionalUS,we confirmed that none of the subjects
had a fatty liver. UsingCEUSwith the lowMI and the highMI
contrastmodes, US images (including those for the portal vein
and the liver parenchyma) were recorded on the hard disk of a
LOGIQ7ultrasound systemby one operator (H.N.) before and
after Sonazoid injection. To minimize the destruction of the
Sonazoidmicrobubbles due to repeated scanning,we recorded
images of the portal vein using cine clips of 2–3 s. Still images
were captured from thecine clips, and the following evaluation
was performed using the still images.
Intensity difference
Using each of the CEUS images obtained using the low MI
and the high MI contrast modes, the operator manually set
each of the ROIs within the right branch of the portal vein
(Fig. 1a) or within the liver parenchyma (Fig. 1b). Using
the intensity obtained from each ROI, we defined the
‘‘intensity difference’’ as the post-injection intensity minus
the pre-injection intensity. Because of slight variations in
the ROI intensity, we performed all measurements three
times and calculated the average intensity, which was used
as the final value [18].
Measurement of the intensity difference of the portal vein
Before and after Sonazoid injection, we set an ROI (with a
diameter of 0.59 cm) at the right branch of the portal vein
and measured the intensity within this ROI at 15 time
points: before Sonazoid injection, 1 min post-injection,
every 10 min up to 60 min (10, 20, 30, 40, 50, and 60 min
post-injection), and then every 30 min up to 300 min (60,
90, 120, 150, 180, 210, 240, 270, and 300 min post-in-
jection). For both the low MI and the high MI contrast
modes, we compared the peak value of the intensity dif-
ference and the intensity difference obtained at other
measurement times. We then compared the intensity dif-
ferences at the portal vein as measured using the low MI
contrast mode with that measured using the high MI con-
trast mode at the 15 different time points described above.
Measurement of the intensity difference in the liver
parenchyma
It was difficult to avoid relatively large portal or hepatic
veins if the ROIs were placed laterally at a depth of 2–4 cm
from the skin surface. To solve this problem, we measured
the intensity of the liver parenchyma using three ROIs,
each with a diameter of 1.2 cm, placed vertically from the
liver surface using both the low MI and the high MI con-
trast modes (Figs. 1b, 2a, b, d, e). The average value of
these three ROIs was then defined as the intensity of the
liver parenchyma. Using each of the CEUS images
obtained using the low MI and the high MI contrast modes,
the intensity difference before and after Sonazoid injection
was then calculated.
Comparison of time course of intensity differences
in the liver parenchyma as measured using the low MI
contrast mode at a low MI
Using the low MI contrast mode, we scanned the liver
parenchyma in Segment 3 at seven time points between
10 min and 300 min post-injection (10, 30, 60, 120, 180,
240, and 300 min). We then compared the peak value of
the intensity difference and those differences obtained at
the other measurement times.
Comparison of the time course of intensity differences
in the liver parenchyma as measured using the high MI
contrast mode at a high MI
Using the high MI contrast mode, we scanned the liver
parenchyma in Segment 8 twice (1 and 10 min post-in-
jection) and in Segment 3 once (300 min post-injection).
We then compared the intensity difference of the liver
parenchyma at each measurement time (1 versus 10, 1
versus 300, and 10 versus 300 min post-injection).
Comparison of the intensity difference in the liver
parenchyma as measured using the low MI contrast mode
at a low MI and using the high MI contrast mode at a high
MI
For the CEUS images obtained using the low MI and the
high MI contrast modes, we scanned the liver parenchyma
at 1 min and at 10 min post-injection in Segment 8 and at
300 min post-injection in Segment 3. We compared the
intensity difference of the liver parenchyma as measured
using the low MI contrast mode with that measured using
the high MI contrast mode at the three measurement times.
Statistical analysis
Data were expressed as the mean ± standard deviation
(SD). The intensity differences between groups (low MI
contrast mode vs. high MI contrast mode) were analyzed
using the independent-samples t test. Individual data
obtained using the low MI and the high MI contrast modes
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(intensity difference at the portal vein, intensity difference
in the parenchyma) were analyzed using a paired t test. The
level of statistical significance was set at P\ 0.05. All the
statistical analyses were performed using SPSS software
version 21 (SPSS, Inc., Chicago, Ill., USA).
Results
Intra-observer variability
This study was evaluated by one examiner and one mea-
surer. The intensities at the portal vein and the liver par-
enchyma were each measured three times. The range of the
three intensity measurements was within 3 %.
Intensity difference at the portal vein
Low MI contrast mode at a low MI
The intensity differences at the portal vein as evaluated using
the low MI contrast mode exhibited a peak value
(mean ± SD: 21.1 ± 5.9 dB) at 1 min after the injection of
Sonazoid. Significant differenceswere observed between the
intensity difference obtained at 1 min post-injection and that
obtained at every other measurement time from 10 to
300 min post-injection (P\ 0.01, each) (Fig. 3).
High MI contrast mode at a high MI
The intensity differences at the portal vein as evaluated
using the high MI contrast mode at a high MI exhibited a
peak value (mean ± SD: 40.6 ± 4.7 dB) at 1 min post-
injection. Significant differences were observed between
the intensity difference obtained at 1 min post-injection
and that obtained at every other measurement time from 10
to 300 min post-injection (P\ 0.01, each) (Fig. 3).
Comparison of intensity difference at the portal vein
as evaluated using the low MI contrast mode at a low MI
and using the high MI contrast mode at a high MI
The intensity differences at the portal vein as evaluated
using the high MI contrast mode were significantly
larger than those evaluated using the low MI contrast
mode at each time point from 1 to 240 min (P\ 0.01)
and at 270 min post-injection (P\ 0.05). No significant
difference was observed at 300 min post-injection
(Fig. 3).
Low MI contrast mode at a low MI
The peak value of the intensity differences in the liver
parenchyma in Segment 3 as evaluated using the low MI
contrast mode occurred at 10 min post-injection. No
Fig. 2 Measurement of the intensity difference in the liver
parenchyma. The upper section shows an image of the liver
parenchyma obtained using the low MI contrast mode at a low MI.
The lower section shows an image of the liver parenchyma obtained
using the high MI contrast mode at a high MI. The images in a,
d show Segment 8 at 1 min post-injection. The images in b, e show
Segment 8 at 10 min post-injection. The images in c, f show Segment
3 at 300 min post-injection. Using the high MI contrast mode, the
intensity differences in the liver parenchyma were similar at 1, 10,
and 300 min post-injection. On the other hand, the intensity
difference of the liver parenchyma at 10 min post-injection using
the low MI contrast mode was higher than those obtained at 1 and
300 min post-injection. All the intensity differences in the liver
parenchyma that were evaluated using the high MI contrast mode
were higher than those evaluated using the low MI contrast mode at
three measurement times (1, 10, and 300 min post-injection)
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significant differences in the intensity difference of the
liver parenchyma were observed from 30 to 120 min post-
injection, compared with the value at 10 min post-injec-
tion. Significant differences in the intensity difference of
the liver parenchyma were observed at 180 (P\ 0.05),
240 (P\ 0.01), and 300 min post-injection (P\ 0.01),
compared with that obtained at 10 min post-injection
(Fig. 4).
High MI contrast mode at a high MI
Using the high MI contrast mode, no significant differences
in the intensity difference of the liver parenchyma were
observed at three measurement times (1 versus 10, 1 versus
300, and 10 versus 300 min post-injection) (Figs. 2, 5).
Comparison of intensity difference in the liver parenchyma
as evaluated using the low MI contrast mode at a low MI
and using the high MI contrast mode at a high MI
The intensity differences in the liver parenchyma as eval-
uated using the high MI contrast mode were significantly
larger than those evaluated using the low MI contrast mode
at three measurement times (P\ 0.01) (Figs. 2, 5). The
mean value of the intensity difference in the liver par-
enchyma at 10 min post-injection as evaluated using the
low MI contrast mode was about 14 dB [Segment 3:
13.0 ± 2.7 dB, Segment 8: 15.7 ± 3.2 dB (mean ± SD)]
(Figs. 4, 5). The mean value of the intensity difference in
the liver parenchyma at 10 min post-injection as evaluated
using the high MI contrast mode was about 40 dB [Seg-
ment 8: 39.3 ± 4.8 dB (mean ± SD)] (Fig. 5).
Discussion
In this study, the intensity differences at the portal vein and
in the liver parenchyma were significantly higher when
evaluated using the high MI contrast mode at a high MI,
compared with the values evaluated using the low MI
contrast mode at a low MI. Furthermore, the high MI
Fig. 3 Intensity differences at
the portal vein as evaluated
using the low MI and the high
MI contrast modes (n = 13).
Significant differences in the
intensity differences at the
portal vein were observed using
the low MI contrast mode and
the high MI contrast mode
between 1 and 270 min post-
injection (P\ 0.05). The
numbers in the graph show the
mean ± SD. ns not significant,
low MI low mechanical contrast
mode, high MI high mechanical
contrast mode
Fig. 4 Comparison of the intensity differences in the liver parench-
yma as evaluated using the low MI contrast mode at each
measurement time in Segment 3 (n = 13). Ten min versus each
time: the intensity difference obtained at 10 min post-injection was
compared with that obtained at each time point. The intensity
differences in the liver parenchyma as evaluated using the low MI
contrast mode showed the maintenance of enhancement from 10 min
post-injection (mean ± SD: 13.0 ± 2.7 dB) to 120 min post-injec-
tion (mean ± SD: 12.1 ± 3.8 dB). The numbers in the graph show
the mean ± SD. ns not significant
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contrast mode at a high MI was more sensitive than the low
MI contrast mode at a low MI for detecting Sonazoid
microbubbles in the liver of normal subjects.
Sasaki et al. [19] reported that the portal vein was
enhanced at between 15 s and 10 min using the low MI
contrast mode after the injection of 0.0075 mL/kg of Sona-
zoid. In our study, all the subjects received an intravenous
bolus injection of 0.2 mL/body of Sonazoid. The peak
intensity difference at the portal vein was observed at 1 min
post-injection using both the lowMI and the highMI contrast
modes. Thereafter, the intensity difference at the portal vein
declined gradually. However, at each time point from 1 to
270 min post-injection, the intensity differences at the portal
vein were significantly larger when evaluated using the high
MI contrast mode at a high MI, compared with evaluations
using the low MI contrast mode at a low MI.
Using the advanced dynamic flow mode (ADF; high MI
contrast mode, MI of 1.6), Sasaki et al. scanned different
planes at eight times (5, 10, 20, 40, 60, 120, 180, and
240 min post-injection) in normal subjects after the injec-
tion of a very small amount (0.000015 mL/kg) of Sonazoid
and reported that the enhancement of the liver parenchyma
lasted from 5 to 120 min [19]. According to their series of
figures [19], the procedure for obtaining ADF-mode ima-
ges might induce Sonazoid microbubble destruction in the
liver parenchyma, even though they scanned different
planes. In our study, however, no significant differences in
the intensity difference of the liver parenchyma were
observed at three measurement times (1, 10, and 300 min
post-injection) when evaluated using the high MI contrast
mode at a high MI since we did not scan the liver par-
enchyma between 10 and 300 min post-injection.
In the present study in subjects with normal livers, the
intensity difference in the liver parenchyma obtained at
10 min post-injection (the same time as the post-vascular
phase) using the high MI contrast mode at a high MI was
about three times higher than that obtained using the low
MI contrast mode at a low MI (40 dB versus 14 dB).
Skyba et al. [20] reported that 0.015 % of all the
microvessels (^7 lm in diameter, mostly capillaries) in rats
were damaged after the destruction of microbubbles con-
taining a mixture of perfluoropropane and air (Optison, GE
Healthcare, Princeton,NJ) during examinations using the high
MI contrast mode (MI 1.0). However, the actual MI value at
the site of microvascular damage in the rats could not be
specified, and interspecies differences in terms of tissue vul-
nerability remain unknown [20]. In the case of clinical
examinations, there have not been any reports describing
microvessel damage after examinations using the high MI
contrast mode in human subjects. However, we cannot com-
pletely rule out the possibility of damage after examination
using the high MI contrast mode. Thus, the low MI contrast
mode is generally preferable for CEUS of the liver. In cases
where diagnostic information can only be obtained using the
high MI contrast mode, the benefits versus the possible
damage should be weighed, and the most appropriate mode
should be selected so as to benefit the subject [21].
After a bolus injection, Sonazoid is carried to the hepatic
artery and the portal vein and flows into the sinusoid, where
most of the Sonazoid microbubbles are phagocytosed by
Kupffer cells [4]. Sonazoid microbubbles that are not
phagocytosed by Kupffer cells are discharged into aspi-
rated air. In rats, more than 50 % of the injected Sonazoid
microbubbles are discharged into aspirated air within
20 min post-injection, and more than 96 % of the injected
Sonazoid microbubbles are discharged into aspirated air
within 24 h post-injection [3]. In humans, we know that
Sonazoid microbubbles are recirculated to the hepatic
artery and the portal vein [6]. In this study, the intensity
differences in the liver parenchyma as evaluated using the
low MI contrast mode did not decrease from 10 to 120 min
post-injection, perhaps because the percentage of recircu-
lating Sonazoid microbubbles was greater than the per-
centage that were lost as a result of the destruction caused
by repeated scans, exhaled in air, and so on.
The recommended dose of Sonazoid for liver tumor
enhancement is 0.015 mL/kg. This dose was determined
based on clinical research conducted approximately
12 years ago [11]. The development of US equipment has
enabled the image quality of CEUS with Sonazoid to be
sufficiently good at doses lower than this recommended
Fig. 5 Comparison of the intensity differences in the liver parench-
yma in Segment 3 and Segment 8 as evaluated using the low MI and
the high MI contrast modes at each measurement time (n = 13).
Significant differences in the intensity differences were observed
between the values obtained using the low MI and the high MI
contrast modes (P\ 0.01). The intensity differences in the liver
parenchyma observed at three time points using the high MI contrast
mode were not significantly different. The numbers in the graph show
the mean ± SD. low MI low mechanical contrast mode, high MI high
mechanical contrast mode
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dose [6]. Numata et al. reported that the use of Sonazoid at
a dose of 0.2 mL/body was sufficient for the evaluation of
liver tumors [6, 12–16]. Therefore, we used this dose in the
present study. If the recommended dose of Sonazoid had
been used in this study, the Sonazoid microbubbles at the
portal vein and in the liver parenchyma might have been
detectable for an even longer time.
Our study had some limitations. First, this study was
conducted prospectively; however, the overall number of
normal subjects included was relatively small. Second,
patients with fatty liver and liver cirrhosis were not included.
Future research examining a larger number of patients with
chronic liver disease is needed to expand on our results.
Third, we did not evaluate several segments of the right lobe
to avoid the influence of microbubble destruction caused by
the scanning of segment 8 using the highMI contrast mode at
10 min post-injection or later. Therefore, we only compared
the intensity difference of the liver parenchyma between the
lowMI and the highMI contrastmodes at threemeasurement
points during this study.
Conclusion
Compared with the low MI contrast mode at a low MI, the
high MI contrast mode at a high MI was more sensitive for
detecting Sonazoid microbubbles in the livers of the nor-
mal subjects evaluated in this study.
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